An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease
Latest Information Update: 10 Dec 2020
Price :
$35 *
At a glance
- Drugs Emlenoflast (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Inflazome; Roche
- 02 Dec 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 02 Dec 2020 Status changed from not yet recruiting to discontinued.
- 17 Sep 2020 Planned End Date changed from 1 Sep 2020 to 1 Nov 2020.